Abstract
The effect of therapy with a combination of tenofovir and full-dose didanosine on increases in CD4+ cell count was examined in 2 large trials of treatment-experienced patients with human immunodeficiency virus (HIV) infection (the T-20 versus Optimized Regimen Only [TORO] 1 and 2 clinical trials). Individuals receiving both agents showed little additional increase in CD4+ cell count after week 8 of therapy, whereas those receiving 1 or neither of the agents had continuous increases over a 48-week period. © 2005 by the Infectious Diseases Society of America. All rights reserved.
Original language | English |
---|---|
Pages (from-to) | 901-905 |
Journal | Clinical Infectious Diseases |
Volume | 41 |
DOIs | |
Publication status | Published - 15 Sep 2005 |